Arcus Biosciences (RCUS) Q3 2026 earnings summary

Executive summary

• Late-stage oncology programs center on casdatifan in clear-cell renal cell carcinoma (ccRCC) and quemliclustat in first-line metastatic pancreatic cancer; the immunology pipeline is expanding.

• October ARC-20 data supported casdatifan activity across ccRCC treatment lines, with no unexpected safety signals at the data cutoff.

• The portfolio spans multiple treatment lines and combines wholly owned programs with regional rights and partnerships.

Financial highlights

• Q3 revenue was $9M vs. $26M YoY; license and development services revenue was $8M vs. $20M, and other collaboration revenue was $1M vs. $6M.

• Q3 R&D expense was $117M vs. $141M YoY, G&A was $23M vs. $27M, and total operating expenses were $140M vs. $168M.

• Q3 net loss was $128M vs. $135M, and diluted loss per share was $1.00 vs. $1.27.

• Nine-month revenue was $67M vs. $214M; net loss was $347M vs. $247M.

• September 30 cash, cash equivalents and marketable securities were $694M; October’s offering generated $288M gross proceeds and $270M net proceeds.

Outlook and guidance

• Cash and investments plus October offering proceeds are expected to fund planned operations into 2029; expected FY 2026 GAAP revenue is $70M–$75M.

• PEAK-1, the Phase 3 casdatifan plus cabozantinib study in 2L ccRCC, is fully enrolled; PEAK-20 is expected to initiate in Q4 2026.

• PRISM-1 completed enrollment; its Phase 3 interim analysis in 1L metastatic pancreatic cancer is expected in Q4 2026.

• 2027 plans include more mature ARC-20 data and early data for casdatifan combinations with ivonescimab and tivozanib; PEAK-1 Phase 3 data and casdatifan plus tivozanib data are anticipated in 2028.

• R&D expense is expected to remain relatively consistent near term as increased casdatifan and immunology investment offsets decreases in other programs.